Abelacimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human anti-factor XI (FXI) monoclonal antibody, with potential anti-thrombotic activity. Upon administration, abelacimab targets and binds to the catalytic domain of FXI, thereby inactivating FXI, and also inhibits the activated form of FXI factor XIa. This prevents the activation of factor XIIa (FXIIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.

**Synonyms:** - ABELACIMAB - MAA 868 - MAA-868 - MAA868